Rechallenge With 177 Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant and Hormone-sensitive Prostate Cancer : Lessons From a Multicase Experience.

Clin Nucl MedJul 13, 2026 (epub)
Case ReportOncology (Medical)

Faeze Rabani, Nikoo Rezaei, Amin Tanha Saber et al.

✦ AI-curated · Sources linked

Case in brief

Four patients with metastatic hormone-sensitive and castration-resistant prostate cancer were treated with 177 Lu-PSMA-617 radioligand therapy. Initial treatment resulted in significant declines in PSA levels, pain relief, and positive radiographic responses. Following disease progression, rechallenge with additional cycles of 177 Lu-PSMA led to renewed PSA reductions and sustained symptomatic improvement, with no severe toxicities observed.

Diagnostic / clinical pearl

Rechallenge with 177 Lu-PSMA-617 radioligand therapy can be effective in patients with metastatic prostate cancer who have previously progressed after initial treatment.

Why it matters

This case highlights the potential for effective retreatment strategies in advanced prostate cancer, suggesting that prior exposure to radioligand therapy does not eliminate the possibility of future benefits.

Source

PubMed · PMID 42544985

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.